An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
When moderator Dr. Peter N. Burns asked those in the 200-plus crowd to raise their hands if they thought the plug should not be pulled on ultrasound contrast, not more than a dozen physicians kept theirs down. When Burns asked to see the hands of those who thought contrast should be let go, only one went up.
A panel composed of Drs. Burns and Stephanie R. Wilson from Canada, Luigi Solbiati from Italy, and Myron A. Pozniak from Madison, WI, discussed the regulatory approval status for contrast-enhanced sonography around the world, its clinical applications, and the arguments in favor of and against the technique.
After the panel discussion and the symbolic voting, members of the audience shared commentaries. Most agreed that the technique is useful and valuable in multiple imaging subspecialties: musculoskeletal, ob/gyn, cardiovascular, and interventional radiology, to name only a few. They also agreed, however, that the reimbursement landscape in the U.S. overwhelmingly favors CT and MR imaging over sonography, which is still considered a time-consuming and operator-dependent modality.
Many said the choice is inevitable. But it could also be harmful to radiology.
"The FDA does not get any benefit from saying 'yes' and having a complication or something negative occur. And there is no cost to them to saying 'no.' The constituency for this is outside radiology," an audience member said. "But then everybody else will end up doing ultrasound and in the future radiologists will be relegated to the sidelines by other subspecialists, who will be doing diagnostic studies using contrast ultrasound."
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.